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Introduction
Fluticasone furoate (6α,11β,16α,17α)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate is a new enhanced-affinity glucocorticoid receptor agonist. It is a synthetic fluorinated corticosteroid that has been developed as an intranasal treatment for patients with symptoms of rhinitis. Fluticasone furoate, otherwise known as GW685698X, is not a salt or prodrug, because the entire molecule is required for pharmacological activity. It has similar or greater potency than other clinically used corticosteroids (including mometasone furoate, budesonide, fluticasone propionate and the active principle of ciclesonide) for the glucocorticoid receptor and against the pro-inflammatory transcription factors nuclear factor κB (NFκB), activation protein-1 (AP-1), and tumour necrosis factor-induced interleukin-8 cytokine production (Salter et al., 2007) . Agonism of the glucocorticoid receptor is known to suppress the activation of downstream transcription factors, such as NFκB and AP-1, and to activate the glucocorticoid response element transactivation pathway (Rhen and Cidlowski, 2005) . Inhibition of the NFκB pathway, in particular, is thought to be intimately involved in the anti-inflammatory activity of glucocorticoids, because it is a key pathway in the synthesis of a number of inflammatory cytokines (Karin et al., 2004) . It is well documented that topical glucocorticoids interact with many of the inflammatory pathways, and there is a large body of clinical evidence to support their use for the treatment of rhinitis, asthma and chronic obstructive pulmonary disease (Goodman and Gilman, 2006) . The purpose of the present study was to investigate the metabolism and disposition of [ 14 C] fluticasone furoate after oral and intravenous administration to healthy male subjects. These dose routes were used as surrogates for the intranasal and inhalation routes, from which the majority of the dose is likely to be This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Materials. Fluticasone furoate, [ 14 C] fluticasone furoate (see Fig. 1 ), and GW694301X, GSK728920A, GSK728921A and GSK728922A (authentic chemicals of possible metabolites of fluticasone furoate) were supplied by Chemical Development, GlaxoSmithKline R&D, Stevenage, UK.
All other solvents and reagents were of analytical grade and were purchased from commercial suppliers.
Formulated Drug. [ 14 C] fluticasone furoate and fluticasone furoate were supplied to the study centre by Pharmaceutical Development, GlaxoSmithKline, Ware, UK, as sterile solutions in propylene glycol. The solutions were at a concentration of 0.25 mg/ml, and with a specific activity of 100 µCi/mg.
For the oral dose the radiolabelled and non-radiolabelled solutions were mixed in a ratio of 1:1.67 to give a dose of 8 ml volume, equivalent to 2 mg fluticasone furoate and approximately 75 µCi.
Subjects and In Vivo Study Design. The clinical part of the study was conducted at
Charles River Laboratories (formerly known as Inveresk), Edinburgh, UK, in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.
All subjects provided written informed consent before participation. The protocol was approved by the investigational centre ethics committee and by the Administration of Radioactive Substances Advisory Committee, UK.
This article has not been copyedited and formatted. The final version may differ from this version. Blood samples were collected via an indwelling cannula or by direct venepuncture into lithium heparin-containing polypropylene tubes.
Following oral dosing, blood samples (10 ml) were collected at 10, 15, 30 and 45 min and 1, 1.5, 2, 3, 5, 9, 12, 24, 48, 72, 96 and 168 h after dosing, with larger samples (30 ml) for metabolic investigations being collected at 0.5, 2 and 12 h. After the start of the intravenous infusion, samples (10 ml) were collected at 15, 30, 32, 35 and 45 min and 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 48, 72, 96 and 168 h after dosing, with the larger samples being collected at 0.75, 1.5 and 12 h. The samples were processed within an hour of collection by centrifugation for 10 min at 1500g at nominally 4°C to yield plasma, which was then stored frozen at nominally -20°C or processed for the determination of radioactivity levels in plasma. Urine samples were collected at 0-6, This article has not been copyedited and formatted. The final version may differ from this version. administration, until 90% of the total radioactive dose administered was recovered from all matrices, or less than 1% of the radioactive dose had been excreted over a 24-h period. The faecal and urine samples were stored frozen at nominally -20°C prior to analysis.
Radioassay of samples.
After measurement of the total sample volume or weight (as appropriate) of excreta, the levels of radioactivity in samples were determined by liquid scintillation counting (Beckman LS series, Bucks, UK or Perkin Elmer Life Sciences instruments, Bucks, UK) with quench correction performed by an automatic external standard ratio method, which was established using sealed 14 C standards.
Aliquots of liquid samples (e.g. urine, dose dilutions) or extracts of samples were mixed with scintillation fluid. Faecal samples were homogenised with an appropriate amount of water. Aliquots of homogenised faecal material were combusted using a Packard model 307 oxidiser prior to radioassay by scintillation counting.
The plasma had low levels of radioactivity; therefore, these samples were diluted appropriately with water and the level of radioactivity determined using accelerator mass spectrometry (AMS).
Determination of Radiochemical Purity. The radiochemical purity of Dose analysis showed that all oral and intravenous doses had a radiochemical purity of 100%.
Quantification of Fluticasone Furoate and GW694301X in Plasma.
Concentrations of fluticasone furoate and GW694301X (M10) in plasma samples were determined using a validated analytical method using in-line solid phase extraction, followed by HPLC and tandem mass spectrometry (HPLC-MS/MS). The validation of this method was performed as detailed for the quantification of fluticasone furoate and GW694301X using similar methodology.
[ 13 C 3 ]-CCI18781 (fluticasone propionate) and GW819063 (10 µl in 20% acetonitrile in water with both at a concentration of 10 ng/ml) were added to plasma samples (0.15 ml) as internal standards. An aliquot of each sample (0.1 ml) was applied to conditioned Prospect C2 cartridges (10 x 1 mm), which were washed with 5% aqueous methanol containing 0.025% formic acid (2 ml) prior to being eluted in-line for 30 seconds onto the analytical column. The cartridge eluant was applied to a HyPurity C18 column (100 x 4.6mm, 5 µM, ThermoHypersil, Runcorn, Cheshire, UK) eluted at a flow rate of 0.5 ml/min using a linear gradient from 100% solvent A to 100% solvent B over 4.3 min, held until 5.15 min prior to returning to 100% solvent A by 6 min. Solvent A was a mixture of methanol and 10 mM ammonium formate (pH 5, 77.5/22.5, v/v) No further analysis of urine samples was conducted, because of the limited amount of radioactive drug-related material in urine.
Radioactive material was extracted from plasma samples using acetonitrile (5 ml per ml of sample, rotary mixed at ambient temperature for approximately 1 h), three times with the supernatants being combined. The extracts were then evaporated to near dryness under a stream of nitrogen prior to being reconstituted in de-ionised water (0.5 or 1 ml). Radioactive material was extracted from faecal samples using alkaline and acidified methanol as described for plasma, and the reconstituted extracts from This article has not been copyedited and formatted. The final version may differ from this version. 11 each extraction method were combined using equal volumes prior to analysis by radio-HPLC. Radio-metabolite profiles were determined by analysis of appropriate aliquots of plasma and faecal extracts by radio-HPLC using on-line or off-line radiodetection.
HPLC method 1 (used for analysis of all matrices.)
The chromatographic instrument used consisted of an Agilent (South Queensferry, Scotland, UK) 1100 binary pump, column oven (40°C), UV detector (λ 245 nm) and auto-sampler (CTC Analytics, or LC PAL injector, both Presearch, Basingstoke, Hampshire, UK ) using a ThermoHypersil Fluophase RP column (250 x 4.6 mm, 5 micron particle size, Runcorn, Cheshire, UK). The mobile phase consisted of 50 mM ammonium acetate (BDH, Poole, Dorset, UK) (pH unadjusted) (solvent A) and acetonitrile (solvent B, supplied by Fisher Scientific, Loughborough, Leicestershire, UK) at a flow rate of 1 ml/min. A gradient was used, starting at 100% A with a linear change to 25% B over 30 min, followed by a linear increase to 40% B by 40 min and then a further increase to 100% by 45 min, with these conditions being held for a further 5 min. The column was re-equilibrated after each injection. Using on-line radiodetection, the column eluate was combined with scintillant (FlowLogic MaxCount supplied by Lablogic, 3 ml/min) prior to detection using a β-Ram (Lablogic, Sheffield, UK) radioactivity monitor. For off-line radiodetection, fractions were collected using a Full recoveries of radioactivity were obtained from the HPLC eluant collected.
HPLC method 2 (used for analysis of human plasma samples).
The chromatographic instrument is as listed for method 1, with the exception of a different column being used: a ThermoHypersil Gold column (250 x 4.6 mm, 5 micron particle size). The mobile phase consisted of 50 mM ammonium acetate pH 5, adjusted using acetic acid (supplied by Fisher Scientific, Loughborough, Leicestershire, UK), (solvent A) and acetonitrile (solvent B) at a flow rate of 1 ml/min. A gradient was used, starting at 25% B with a linear increase to 40% B over 8 min, followed by a linear increase to 45% B by 12 min and then a further increase to 75% by 13 min, held at these conditions for 2 min before increasing to 90% by 18 min. The column was washed and re-equilibrated after each injection. and HPLC fractions were measured by AMS, which measures the radiocarbon content in a sample through separation of the isotopes of carbon present by their different mass-to-charge ratios. Before AMS analysis, the samples were graphitised via a twostep process of oxidation and reduction (Vogel, 1992 furoate at a dose of 2 mg, maximum mean concentrations (C max ) of fluticasone furoate occurred within 30 min (T max ) of administration, indicating rapid oral absorption of the dose. Concentrations declined rapidly thereafter, such that they were below the limit of quantification beyond 9 h (Fig. 2) . After a 30 min intravenous infusion of Table 2 ). Most of the dose was excreted in the faeces for both routes of administration; urinary excretion was a very minor route (< 3%). Radioactivity was eliminated rapidly: most was excreted within the first 72 h post-dose, with approximately 71% and 91% of the dose recovered over that period following intravenous and oral administration, respectively.
Identification of
Metabolite Profiles in Plasma and Faeces. Proposed structure and spectral data supporting metabolite identification are shown in Table 3 . Radioactive drug-related material in plasma is expressed as % sample radioactivity. Radioactive drug-related material in faeces is expressed as % administered dose. Where the sample preparation step resulted in some loss of radioactivity, if the recovery was <90%, the This article has not been copyedited and formatted. The final version may differ from this version. Low levels of radioactivity were present in the human plasma extracts; therefore, the profiling of these samples was performed using AMS as the radioactivity detection method. Representative reconstructed HPLC radiochromatograms of plasma extracts following intravenous and oral administration, at selected sampling times, are shown in Fig. 3 . The extraction efficiency of radioactivity from plasma was in excess of 70% at early time points, but notably lower (9-35%) at later time points.
The principal radiolabelled component in plasma following a single intravenous infusion of [ 14 C] fluticasone furoate was unchanged fluticasone furoate (P), which accounted for at least 52% of radioactive material in plasma samples up to 1.5 h after dosing. The 17β-carboxylic acid metabolite (GW694301X, M10) of fluticasone furoate was assigned based on retention time and represented up to 4% of plasma radioactivity. Three other minor components were also observed, each representing less than 2% of plasma radioactivity.
After oral administration, M10 and fluticasone furoate were the major components in plasma, comprising 28% and 17% of sample radioactivity, respectively, at 0.5 h, and 6% and 7%, respectively, at 2 h post-oral administration. Metabolites M21 (6 hydroxyl of parent), M26 (6 hydroxyl of M10) and M32 (an hydroxylated product of M10) were observed in human plasma, based on their co-elution with either authentic standards or identified metabolites from in vitro incubations; all accounted for less This article has not been copyedited and formatted. The final version may differ from this version. Fig. 3 .
The predominant identified drug-related component in the faecal extracts from four out of five subjects following dosing by either route was M10, representing 32% to 40% of the oral dose and 24% to 31% of the intravenous dose. However, in one subject, M10 was a minor component of the total drug-related material excreted in the faeces. Other drug-related components assigned by co-chromatography with authentic standards were the 6-hydroxy metabolite of M10 (M26) and parent compound, each representing less than 8% of an oral or intravenous dose.
Although most of the dose was excreted in faeces, the absolute amounts of drugrelated material present in the faecal samples were very low. A number of drugrelated components remained insensitive to detection by mass spectrometry and their structures were not elucidated.
This article has not been copyedited and formatted. The final version may differ from this version. (Martin et al., 2007) . As such, it is important to gain an understanding of the metabolism and disposition of fluticasone furoate in humans.
The pharmacokinetic profile of fluticasone furoate following intravenous administration to humans is characterised by a high plasma clearance at 58.3 L/h, which is approximately two-thirds human liver blood flow (Davies and Morris, 1993) , and a very large volume of distribution of 642 L, which equates to approximately fifteen times total body water (Davies and Morris, 1993) , indicating extensive tissue uptake. These properties in combination resulted in a moderate plasma half-life of 15.3 h. In contrast, the plasma half-life observed following oral administration was shorter, at approximately 4 h; however, this is likely to be representative of the distribution phase, with plasma concentrations falling below the assay limit of quantification before the true elimination phase was observed. This is consistent with a large first-pass effect resulting in a very low mean oral bioavailability, calculated at 1.6%. The absolute bioavailability of intranasally administered fluticasone furoate in healthy volunteers has been determined to be 0.5% (Allen et al., 2007) . The lower bioavailability observed with the clinical intranasal formulation is likely as a result of differences in dose, dose route and formulation compared with those used in this study.
Systemic exposure to radioactivity was much greater than systemic exposure to fluticasone furoate for both routes of administration, with the observed difference being greater following oral administration. In addition, the elimination half-life of values for total plasma radioactivity following oral and intravenous administration) may be an over-estimate, because the profiles of drug-related material following the two routes of administration differ; however, it is consistent with the ratios of urinary excretion, although these are based on very low values. A similar extent of absorption was also observed in rats and dogs (unpublished data), where 29% and 19% (30% of the recovered radioactivity) of an oral radioactive dose was recovered in the bile and urine of bile-duct cannulated rats and a dog, respectively.
The principal component in plasma extracts following intravenous administration of [ 14 C] fluticasone furoate (0.25 mg) to healthy male subjects was fluticasone furoate, with low levels of the 17β carboxylic acid metabolite (M10) of fluticasone furoate also observed. In contrast, following oral administration (2 mg) to the same male subjects, M10 and fluticasone furoate were both principal components in the plasma extracts. Three other minor drug-related components (each less than 5% of plasma radioactivity) were observed and were assigned as products of oxidative metabolism.
The greater contribution of metabolites to plasma radioactivity after oral than after intravenous administration is consistent with high first-pass metabolism. The remainder of the plasma radioactivity following intravenous or oral administration was either unextracted or unassigned because of the low levels of drug-related material in the plasma. The unextracted radioactivity represented a very low amount 21 corticosteroids, such as ciclesonide (Nave et al., 2004) and mometasone furoate (Affrime et al., 2000) .
The major route of fluticasone furoate metabolism in humans is ester hydrolysis leading to formation of the 17β carboxylic acid (M10) with loss of the S-fluoromethyl carbothioate moiety. The loss of this moiety is also the significant route of metabolism of fluticasone propionate, with the biotransformation being catalysed by cytochrome P450 3A4 (Pearce et al., 2006) . Oxidative defluorination of fluticasone furoate at the C6 position also occurred and resulted in the formation of M21 and M26; this biotransformation is known to occur in a number of fluorine-containing drugs (Park et al., 2001 ). Oxidative defluorination is also a metabolic pathway for fluticasone propionate in vitro in human-derived preparations (Shenoy et al., 1993) .
Oxidative defluorination of fluticasone furoate resulted in hydroxylation at the C6 position; C6 hydroxylation is a well-precedented route of metabolism for corticosteroids and has been observed in human-derived in vitro systems for budesonide (Jonsson et al., 1995) , mometasone furoate (Teng et al., 2003b) and ciclesonide (Peet et al., 2005) . A summary of the proposed oxidative pathways for fluticasone furoate in humans is shown in Fig. 4 . There was no evidence for metabolic loss of the furoate group from fluticasone furoate or any of its metabolites; this differs to mometasone furoate, where loss of the furoate group is observed with the formation of mometasone in human-derived fluids and tissue preparations (Teng et al., 2003b) and rat-derived fluids and tissue preparations (Teng et al., 2003a) .
Although limited data were obtained from in vivo excreta because of the low amounts of drug-related material present, it was observed that, although oral absorption of fluticasone furoate in human was at most approximately 30%, little or no unchanged parent drug was observed in the faeces after oral administration. A similar pattern was Most of an intranasal or inhaled dose is likely to be swallowed; therefore, the oral and intravenous routes of administration were considered adequate surrogate routes from which to obtain samples to define the major routes of metabolism of fluticasone furoate in humans. The oral route acted as a surrogate for the portion of an intranasal or inhaled dose that is swallowed, and the intravenous route represented the drug that is absorbed locally into the systemic circulation. This article has not been copyedited and formatted. The final version may differ from this version. 
